Emobot

Name

Emobot

Legal name

EMOBOT SAS

Website

https://emobot.fr

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Digital Mental Health — Mood Disorder Monitoring & Digital Therapeutics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• Digital mental health
• Mood disorder diagnostics
• AI emotion recognition
• Digital therapeutics
• Depression monitoring software

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. B2B SaaS / Software Licensing: Emobot licenses its EMOCARE and EmoDTx platforms to healthcare providers (clinics, hospitals), pharmaceutical companies for clinical trial endpoints, and nursing home networks. Revenue model likely subscription-based per clinic or per patient, though specific pricing not publicly disclosed.
2. Clinical Endpoint Services for Pharma: Provision of objective, continuous mood measurement as a digital endpoint for pharmaceutical clinical trials, helping pharma companies reduce trial risk (10-250M USD per Phase II/III trial) and improve drug development outcomes.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Emobot develops and licenses Class IIa medical device software — EmoCare, a passive smartphone-based "depression thermometer" that continuously estimates mood-disorder severity through AI-driven facial expression and voice analysis, and EmoDTx, a digital therapy combining cognitive behavioral therapy with automated mood self-tracking. The products are sold to healthcare providers, pharmaceutical companies running clinical trials, and nursing homes.

Product overview

Emobot offers two integrated medical devices: EmoCare (diagnostic monitoring tool) and EmoDTx (digital therapy). Both products use the same underlying passive monitoring technology—smartphone-based facial expression analysis and voice intonation tracking—to measure mood continuously. EmoCare serves as the diagnostic and monitoring component, while EmoDTx adds cognitive behavioral therapy features on top, creating a combined diagnostic-therapeutic platform for depression and bipolar disorder management.

Differentiator

Problem solved

Functional benefit

Products and services

• EmoCare EmoCare is a smartphone-based diagnostic and monitoring tool ("depression thermometer") that passively estimates mood-disorder severity through AI-driven facial expression and voice intonation analysis. Achieved 0.895 within-person concordance with clinician-rated MADRS assessments in clinical validation. Functions as a digital endpoint for depression monitoring and is sold to hospitals, interventional psychiatry clinics, pharmaceutical companies, and nursing home networks.
• EmoDTx EmoDTx is a Class IIa digital therapeutic (DTx) medical device combining cognitive behavioral therapy with automated mood self-tracking using the same passive facial and voice analysis underlying EmoCare. It serves as a diagnostic aid, treatment aid, and clinical endpoint for patients undergoing psychiatric care, particularly those with depression and bipolar disorders.

Quantifiable outcome

• 0.895 within-person concordance with clinician-rated MADRS scores (90% correlation)
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

15 partnerships are on record, tiered core, major and minor.

• NRx Pharmaceuticals / Hope TherapeuticscoreStrategic or Co-development Partner · 30 March 2026Strategic partnership with NRx Pharmaceuticals for deployment of EMOCARE AI-powered depression monitoring platform across the Hope Therapeutics interventional psychiatry clinic network. Hope Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals. The technology serves as a patient self-monitoring and safety-net tool for treatment-resistant depression, providing clinicians continuous real-time insight into patient response between visits.
• AIMAC Laboratory, CentraleSupélec, IETR, CNRScoreStrategic or Co-development Partner · 1 January 2022Long-standing research partnership with AIMAC (Artificial Intelligence for Multimodal Affective Computing) team at CentraleSupélec directed by co-founder Renaud Seguier. Develops algorithms, digital signals, and biomarkers for automatic estimation of mood disorder severity. Framework partnership for scientific support and AI/emotion R&D.
• GHU Paris Psychiatrie & NeurosciencescoreStrategic or Co-development PartnerClinical collaboration with Pr. Fabien Vinckier's service at GHU Paris for the Moodeling study — evaluation of EmoDTx for continuous mood tracking in patients with depression and treatment-resistant schizophrenia. Investigator: Pr. Fabien Vinckier, PU-PH, researcher at ICM.
• Hôpital Guillaume Régnier and INCR (Institut des neurosciences cliniques de Rennes)majorStrategic or Co-development PartnerCollaboration with Pr. Gabriel Robert (neuropsychiatrist) and Dr. Jean-Marie Batail (MCU-PH) at Hôpital Guillaume Régnier for clinical validation of Emobot's mood monitoring technology.
• Bridge Group (EHPAD Nursing Homes)majorStrategic or Co-development PartnerPartnership and co-development with Bridge Group, a group of nursing homes. Currently 30 robots deployed at nursing home Le Val Fleuri. Bridge Group is interested in Emobot for monitoring emotional health of residents and detecting 'syndrome du glissement' (precipitous behavioral decline in elderly).
• GCSMS Comete Bretagne (groupement d'EHPAD)majorStrategic or Co-development PartnerStrategic partnership with the Breton nursing home group GCSMS Comete Bretagne, Gérontopôle, and Living Lab (LL2V). Joint application submitted for AAP Structures 3.0 to equip 140 robots across 12 nursing homes in Finistère and Morbihan departments.
• Station FmajorStrategic or Co-development PartnerIncubated at Station F (world's largest startup campus) as part of the 10th cohort of the Pépite Start'up Île-de-France acceleration program. iPEPS (Paris Brain Institute incubator) partnership on digital health with Station F.
• iPEPS — Paris Brain Institute Startup IncubatormajorStrategic or Co-development PartnerIncubated at iPEPS (the HealthTech Hub at Institut du Cerveau / ICM) since October 2022. First innovation accelerator dedicated to brain diseases in France, part of IHU and Carnot networks. Located within Hôpital de la Pitié-Salpêtrière.
• Gérontopôle of Île-de-France RegionminorStrategic or Co-development PartnerEmobot is one of the innovations of the Gérontopôle Living Lab, supported and promoted in collaborative projects and calls for projects in favor of innovations for aging well.
• Fondation FondaMentalmajorStrategic or Co-development PartnerCollaboration with Pr. Marion Leboyer, psychiatrist and Director of FondaMental Foundation (Grand Prix Inserm 2021), for research on mood disorders and clinical validation of Emobot's technology.
• CHU NantesmajorStrategic or Co-development PartnerClinical collaboration with Pr. Anne Sauvaget, psychiatrist and PU-PH at CHU Nantes.
• Université Paris-Saclay / CentraleSupéleccoreStrategic or Co-development PartnerUniversité Paris-Saclay is ranked 13th globally. CentraleSupélec (1st French engineering school) is a key ecosystem partner. Emobot co-founders are engineers from CentraleSupélec, and the AIMAC research laboratory is based there.
• Cap DigitalminorStrategic or Co-development PartnerCompetitiveness and digital transformation cluster in Île-de-France supporting Emobot's development since September 2022.
• Centre médical universitaire de Hambourg (UKE)minorStrategic or Co-development PartnerCollaboration with Dr. Steffen Moritz, psychiatrist and neuropsychologist at UKE Hamburg, specialist in digital therapies (DTx), for international clinical validation.
• Île-de-France RegionmajorGTM or Marketing PartnerSupported by the Île-de-France Region as a key player in Silver Economy. Featured on the Region's stand at CES 2023 and VivaTech. Region views Emobot as responding 'in an original way to an issue that has a particular resonance at the moment.'

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Kintsugi Health: Kintsugi develops voice-based biomarkers and machine learning models to detect depression and anxiety from short voice samples, positioning it as a direct competitor in AI-driven passive mood monitoring for clinical and pharma use cases.
• Ellipsis Health: Ellipsis Health analyzes voice and speech patterns to identify signs of depression and anxiety, mirroring Emobot's voice-based biomarker approach for mental health screening and monitoring in clinical and payer settings.
• Woebot Health: Woebot Health delivers FDA-cleared digital therapeutics for mental health, combining AI-driven CBT with patient engagement tools. Comparable to Emobot's EmoDTx as a regulated DTx for depression and related conditions.
• Big Health: Big Health builds FDA-cleared digital therapeutics (e.g., Sleepio, Daylight) for mental health conditions including insomnia and anxiety, competing for the same payer, pharma, and prescriber relationships Emobot targets with EmoDTx.
• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics for mental health and other indications, with pharma partnerships for trial and commercialization support — directly comparable to Emobot's DTx + pharma endpoint model.
• Akili Interactive: Akili Interactive has developed FDA-cleared digital therapeutics (e.g., EndeavorRx) and is expanding into adult mental health indications, making it a comparable regulated DTx competitor pursuing pharma and payer partnerships.
• Sonde Health: Sonde Health builds vocal biomarker technology to detect and monitor mental and physical health conditions from voice, directly comparable to Emobot's voice-based biomarker analysis for mood and depression monitoring.

Emerging players

• Limbic: Limbic applies AI to mental health self-referral and patient-facing tools for NHS talking therapies in the UK. Overlaps with Emobot in using AI to improve mental health assessment and access, though focused on intake rather than continuous monitoring.
• Smart Eye (Affectiva): Smart Eye acquired Affectiva, a pioneer in facial expression and emotion AI. Affectiva's underlying technology overlaps with Emobot's facial emotion analysis and is being adapted to health, automotive, and research applications.

Broad incumbents

• Otsuka Pharmaceutical (Digital Health): Otsuka developed and commercialized Abilify MyCite, the first FDA-approved digital pill, and has broad mental health pharma plus digital therapeutics ambitions, serving as a broad incumbent that competes for digital endpoint and DTx mindshare.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/EmobotRobot
• YouTubeyoutube.com/channel/UCVxTEI-JyWAvnZo5U8dFTGQ
• LinkedInlinkedin.com/company/emobot
• Facebookfacebook.com/emobot.robot

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emobot